Literature DB >> 1384363

Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma.

A J Stingo1, A L Clavell, D M Heublein, C M Wei, M R Pittelkow, J C Burnett.   

Abstract

The present study was undertaken to investigate the presence of C-type natriuretic peptide (CNP) immunoreactivity in cultured human vascular endothelial cells and in human plasma. CNP immunoreactivity was present in cultured human aortic endothelial cells by both immunohistochemical staining and by radioimmunoassay. With the utilization of gel permeation chromatography, this immunoreactivity proved to be consistent with the higher molecular weight CNP-53. CNP immunoreactivity was also present in human plasma (n = 22) at low picogram concentrations (6.5 +/- 0.2 pg/ml) by specific radioimmunoassay. This immunoreactivity was consistent with the lower molecular weight CNP-22 by gel permeation chromatography. These findings suggest that the vascular endothelium may be the site of CNP production. The isolation of different molecular forms of CNP in tissue and plasma may be consistent with a storage form of the peptide in endothelial cells CNP-53, while CNP-22 circulates in plasma. In summary, the present study is consistent with CNP being a peptide of endothelial cell origin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384363     DOI: 10.1152/ajpheart.1992.263.4.H1318

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  50 in total

1.  The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide.

Authors:  S Jeson Sangaralingham; Brenda K Huntley; Fernando L Martin; Paul M McKie; Diego Bellavia; Tomoko Ichiki; Gerald E Harders; Horng H Chen; John C Burnett
Journal:  Hypertension       Date:  2010-12-28       Impact factor: 10.190

Review 2.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

Review 3.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

4.  Serum NT-pro CNP levels in epileptic seizure, psychogenic non-epileptic seizure, and healthy subjects.

Authors:  Mustafa Ceylan; Ahmet Yalcin; Omer Faruk Bayraktutan; Esra Laloglu
Journal:  Neurol Sci       Date:  2018-09-19       Impact factor: 3.307

Review 5.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

6.  B-Type and C-type natriuretic peptides modify norepinephrine uptake in discrete encephalic nuclei of the rat.

Authors:  M R Fermepín; M S Vatta; L G Bianciotti; T J Wolovich; B E Fernández
Journal:  Cell Mol Neurobiol       Date:  2000-12       Impact factor: 5.046

7.  C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure.

Authors:  R I Cargill; C S Barr; W J Coutie; A D Struthers; B J Lipworth
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

8.  Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide.

Authors:  C M Wei; C H Kim; V M Miller; J C Burnett
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis.

Authors:  Tomoko Ichiki; Guido Boerrigter; Brenda K Huntley; S Jeson Sangaralingham; Paul M McKie; Gail J Harty; Gerald E Harders; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

10.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

Authors:  Ondrej Lisy; Brenda K Huntley; Daniel J McCormick; Paul A Kurlansky; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.